These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25777468)

  • 21. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
    BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
    Gupta N; Hanley MJ; Venkatakrishnan K; Perez R; Norris RE; Nemunaitis J; Yang H; Qian MG; Falchook G; Labotka R; Fu S
    Br J Clin Pharmacol; 2016 Sep; 82(3):728-38. PubMed ID: 27121262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
    Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
    J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
    Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
    Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
    Kato S; Adashek JJ; Subbiah V; Fu S; Sun M; Nguyen L; Brown EJ; Yap TA; Karp DD; Piha-Paul SA; Hong DS
    Invest New Drugs; 2022 Feb; 40(1):99-105. PubMed ID: 34468905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
    Machida M; Fukunaga S; Hara T
    Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
    Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D; Raje N; Byrne C; Liao E; Gupta N; Bacco AD; Estevam J; Berg D; Baz R
    Br J Haematol; 2018 Jul; 182(2):231-244. PubMed ID: 29938772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
    Papadopoulos KP; Burris HA; Gordon M; Lee P; Sausville EA; Rosen PJ; Patnaik A; Cutler RE; Wang Z; Lee S; Jones SF; Infante JR
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):861-8. PubMed ID: 23975329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixazomib - the first oral proteasome inhibitor.
    Xie J; Wan N; Liang Z; Zhang T; Jiang J
    Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
    Dimopoulos MA; Špička I; Quach H; Oriol A; Hájek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng WJ; Leleu X; Iida S; Mateos MV; Morgan G; Vorog A; Labotka R; Wang B; Palumbo A; Lonial S;
    J Clin Oncol; 2020 Dec; 38(34):4030-4041. PubMed ID: 33021870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
    Schwartz G; Shee K; Romo B; Marotti J; Kisselev A; Lewis L; Miller T
    Oncologist; 2021 Jun; 26(6):467-e924. PubMed ID: 33641211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixazomib-induced cutaneous necrotizing vasculitis.
    Alloo A; Khosravi H; Granter SR; Jadeja SM; Richardson PG; Castillo JJ; LeBoeuf NR
    Support Care Cancer; 2018 Jul; 26(7):2247-2250. PubMed ID: 29392482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
    Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
    Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
    Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
    Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
    Wang Y; Janku F; Piha-Paul S; Hess K; Broaddus R; Liu L; Shi N; Overman M; Kopetz S; Subbiah V; Naing A; Hong D; Tsimberidou AM; Karp D; Yao J; Fu S
    Sci Rep; 2020 Feb; 10(1):3080. PubMed ID: 32080210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
    Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.